Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Zhifei Biological Renews Exclusive China Distribution Pact with Merck for Gardasil 9, Rotateq, and Pneumovax—Shifts to Demand-Driven Supply Model

Fineline Cube Apr 3, 2026
Company Deals Digital

Xellar Biosystems Closes RMB 200M Series A Led by China Life Investment to Build 3D Bio Intelligence Platform

Fineline Cube Apr 3, 2026
Company Deals

Regeneron Partners with TriNetX in $200M Deal to Expand World-Leading Genomic-Phenotypic Data Platform

Fineline Cube Apr 3, 2026
Company Deals

Biocytogen and Sihuan Pharma Forge Strategic Partnership to Accelerate Innovative Drug Development Including Weight Management Therapies

Fineline Cube Apr 2, 2026
Company Deals

Sanli Pharmaceutical Transfers Marketing Rights for 16 Drugs to Hanfang Pharmaceutical in RMB 2 Million Deal

Fineline Cube Apr 2, 2026
Policy / Regulatory

China’s CDE Releases 105th Batch of Reference Preparations for Generic Drug Evaluation, Adds 8 New Drugs

Fineline Cube Apr 2, 2026
Company Drug

AstraZeneca’s Imfinzi-Imjudo Combo with Lenvatinib and TACE Shows Significant PFS Benefit in Early-Stage Liver Cancer, EMERALD-3 Trial Reveals

Fineline Cube Apr 3, 2026
Company Drug

RemeGen Secures NMPA Approval for Phase I/IIa Trial of Bispecific ADC RC288 Targeting PSMA and B7H3 in Solid Tumors

Fineline Cube Apr 2, 2026
Company

Sichuan Kelun-Biotech Reports 25.5% Revenue Growth with Key Drug Approvals

Fineline Cube Mar 25, 2025

China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has released its 2024 financial report, recording...

Drug Medical Device Policy / Regulatory

China’s NHSA Releases 2024 Healthcare Security Bulletin Highlighting Insurance Coverage and Reimbursement

Fineline Cube Mar 25, 2025

China’s National Healthcare Security Administration (NHSA) has released its 2024 “Healthcare Security Development Statistical Bulletin.”...

Company Medical Device

Jenscare Scientific’s Ken Valve Receives NMPA Marketing Approval

Fineline Cube Mar 25, 2025

Jenscare Scientific Co., Ltd (HKG: 9877), a Ningbo-based structural heart disease device maker, has announced...

Company Drug

SineuGene Therapeutics’ SNUG01 Receives FDA Clearance for ALS Clinical Study

Fineline Cube Mar 25, 2025

Beijing-based SineuGene Therapeutics, a developer of gene therapies for brain disorders, announced last week that...

Company Drug

GSK’s Nucala Accepted for EMA Review for COPD Treatment

Fineline Cube Mar 25, 2025

UK-based GSK plc’s (LON: GSK, NYSE: GSK) application for expanding the use of its anti-interleukin-15...

Company Deals

Opella and JD Healthcare Collaborate to Enhance Fatty Liver Awareness in China

Fineline Cube Mar 25, 2025

Opella, the consumer health business of French giant Sanofi (EPA: SAN, NASDAQ: SNY), held a...

Company Deals

Chongqing Zhifei Acquires 51% Stake in Chenan Bio for RMB593 Million

Fineline Cube Mar 25, 2025

Chongqing Zhifei Biological Co., Ltd (SHE: 300122), the distribution partner for US giant Merck’s Gardasil...

Company Drug

Shanghai Ark Biopharmaceutical’s AK0901 Meets Phase III Endpoints in ADHD Trial

Fineline Cube Mar 25, 2025

China’s Shanghai Ark Biopharmaceutical Co., Ltd. has announced the completion of a Phase III study...

Company

WuXi XDC Reports 90.8% Revenue Surge, Expanding in ADC Market

Fineline Cube Mar 25, 2025

WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA...

Company Drug

Suzhou Xueji Biotech’s XJ-MK-002 Gets FDA Orphan Drug Designation for CAMT

Fineline Cube Mar 25, 2025

China-based cell therapy developer Suzhou Xueji Biotechnology Co., Ltd’s (HemaCell) XJ-MK-002, described as the world’s...

Company Drug

Beijing Sungen Biomedical’s SGC001 Receives FDA Fast Track Designation for AMI Treatment

Fineline Cube Mar 25, 2025

China-based Beijing Sungen Biomedical Technology Co., Ltd, an antibody developer incubated by Hotgen Biotech Co.,...

Company Deals

CanSino Biologics Partners with Grand Life Sciences to Commercialize Tetanus Vaccine in Greater China

Fineline Cube Mar 25, 2025

Chinese firms CanSino Biologics Inc. (HKG: 6185) and Grand Life Sciences have entered into an...

Company Drug

AllianThera Biopharma Starts Global Phase I Trial for ATB102 in Inflammatory Bowel Diseases

Fineline Cube Mar 24, 2025

Suzhou-based startup AllianThera Biopharma has announced the first patient dosing in a global Phase I...

Company Drug

Jiangsu Hengrui Pharmaceuticals’ Ivarmacitinib Receives NMPA Approval for Ankylosing Spondylitis

Fineline Cube Mar 24, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced receiving marketing approval from the National...

Company Medical Device

Oriomics’ Liver Cancer Screening Reagent Earns FDA Breakthrough Device Designation

Fineline Cube Mar 24, 2025

Hangzhou-based Oriomics, a cancer screening specialist backed by Hotgen Biotech Co., Ltd (SHA: 688068), has...

Company Deals Drug

Kexing Biopharm Partners with BioMap on AI-Driven Macromolecular Drug Development

Fineline Cube Mar 24, 2025

China-based Kexing Biopharm Co., Ltd. (SHA: 688136) announced a partnership with US biotech firm BioMap...

Company Drug

CStone Pharmaceuticals Files for EMA Approval of Sugemalimab for Unresectable Stage III NSCLC

Fineline Cube Mar 24, 2025

China-based CStone Pharmaceuticals (HKG: 2616) has announced filing for another indication approval for its anti-programmed...

Company Deals

Abbisko Therapeutics and Allist Pharmaceuticals Partner on KRAS-G12C NSCLC Combination Therapy

Fineline Cube Mar 24, 2025

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has entered into a cooperation agreement with...

Company

Eli Lilly Launches Lilly Gateway Laboratory in China to Boost Biotech Innovation

Fineline Cube Mar 24, 2025

US major Eli Lilly & Co., (NYSE: LLY) has announced the opening of the Lilly...

Company Drug

Clover Biopharmaceuticals Receives FDA Approval for SCB-1019 RSV Vaccine Trial

Fineline Cube Mar 24, 2025

China-based Clover Biopharmaceuticals Ltd., (HKG: 2197) has announced receiving clinical approval from the US Food...

Posts pagination

1 … 170 171 172 … 646

Recent updates

  • Zhifei Biological Renews Exclusive China Distribution Pact with Merck for Gardasil 9, Rotateq, and Pneumovax—Shifts to Demand-Driven Supply Model
  • Xellar Biosystems Closes RMB 200M Series A Led by China Life Investment to Build 3D Bio Intelligence Platform
  • Regeneron Partners with TriNetX in $200M Deal to Expand World-Leading Genomic-Phenotypic Data Platform
  • AstraZeneca’s Imfinzi-Imjudo Combo with Lenvatinib and TACE Shows Significant PFS Benefit in Early-Stage Liver Cancer, EMERALD-3 Trial Reveals
  • RemeGen Secures NMPA Approval for Phase I/IIa Trial of Bispecific ADC RC288 Targeting PSMA and B7H3 in Solid Tumors
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Zhifei Biological Renews Exclusive China Distribution Pact with Merck for Gardasil 9, Rotateq, and Pneumovax—Shifts to Demand-Driven Supply Model

Company Deals Digital

Xellar Biosystems Closes RMB 200M Series A Led by China Life Investment to Build 3D Bio Intelligence Platform

Company Deals

Regeneron Partners with TriNetX in $200M Deal to Expand World-Leading Genomic-Phenotypic Data Platform

Company Drug

AstraZeneca’s Imfinzi-Imjudo Combo with Lenvatinib and TACE Shows Significant PFS Benefit in Early-Stage Liver Cancer, EMERALD-3 Trial Reveals

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.